

Synthesis, Spectra and Antibacterial Studies of Ni(II), Fe(II) and Co(II) Complexes of 5-(4-Chlorophenyl)-6-Ethyl-2,4-Pyrimidinediamine

Amadi Kelvin Okoche¹, Otuokere Ifeanyi Edozie², Okorie Uloma Glory³,
1 Lecturer, 2 Senior Lecturer, 3 Student

Department of Chemistry, Michael Okpara University of Agriculture, Umudike, NIGERIA
amadikelvin77@gmail.com, ifeanyiotuokere@gmail.com, tosmanbaba@yahoo.com

ABSTRACT:

5-(4-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine (pyrimethamine) is a preventive and curative drug for the treatment of parasitic infections. Ni(II), Fe(II) and Co(II) complexes of pyrimethamine were synthesized. The melting point, yield, and colour of the metal complexes were determined. The complexes were characterized based on UV-visible and Infrared spectrophotometric analysis. The complexes and the ligand were screened against *Nesseria gonorrhea* and *Proteus mirabilis* at 250, 125 and 65.25 mg/ml concentration. The increase in the melting point and change in the colour of the complexes suggests complexation. The absorption maxima in the electronic spectra of the complexes were assigned intra-ligand charge transfer (ILCT) and ligand to metal charge transfer. Infrared spectra of the Ni(II) and Fe(II) pyrimethamine complexes suggests the involvement of two NH₂ and two C=N functional groups in coordination to the metal. IR spectrum of Co(II) pyrimethamine complex suggested the involvement of two NH₂ functionality in coordination to cobalt. The zone of inhibition of pyrimethamine against *Nesseria gonorrhea* and *Proteus mirabilis* at 250.00, 125.00 and 65.25 mg/l showed that it was significantly lower ($P < 0.05$) than the complexes. The zone of inhibition of Fe(II) pyrimethamine complex against *Nesseria gonorrhea* and *Proteus mirabilis* at 250.00, 125.00 and 65.25 mg/l showed that it was significantly higher ($P < 0.05$) than Ni(II) and Co(II) pyrimethamine complexes. This suggests that the complexes were more potent than the parent ligand against the bacteria strains used.

Key words: Pyrimethamine, antibacteria, complexes, spectroscopic, ligands

INTRODUCTION

Pyrimethamine is a preventive and curative drug for the treatment of parasitic infections [1,2]. Pyrimethamine can be administered in conjunction with sulphadoxine in the treatment of malaria and in the secondary prevention for people with HIV/AIDS [2]. The resistance of pyrimethamine in the treatment of malaria may be caused by mutation in the malaria gene for dihydrofolate reductase [3]. It is an important medication for primary healthcare and it is listed as World Health Organisation's list of essential medicine [4]. It is a dihydrofolate reductase (DHFR) inhibitor since it inhibits folic acid metabolism. The structure of pyrimethamine is shown in Figure 1.




Figure 1: Structure of Pyrimethamine

Metal complexes play an important role in medical science because they activate or biotransform their parent ligand/drug [5]. Antimicrobial activities of metal complexes have been reported by Shelke and Co workers [6]. They reported that the complexes exhibited enhanced antimicrobial activity than the parent ligand [6]. The research on transition metal

complexes is unending because they possess pharmacological properties [7-9]. Structural modification of bio-ligands with metal ions are of interest because the metal ions increase the activity of the bio-ligands. Recent research has shown significant progress in the use of chelated complexes to treat diseases [10]. The rapid spread of drug-resistant antibacterial worldwide has stimulated the search for new drugs to treat millions of people infected with the bacteria's. There is an urgent need for antibacterial with novel structures, modes of action or both to deal with the development of resistance to the drugs in current use. Previous research has shown that attaching organic drugs to metal-containing fragments could enhance their activity against diseases.

In our effort towards the development of metal based drugs, we decided to synthesize metal complexes of pyrimethamine, characterize these complexes and determine the inhibition of the bacteria activities on the complexed metal in comparison with the ligand. This synthetic strategy involves modification of the activity of pyrimethamine through the incorporation of a transition metal into the molecular structure. This modification in the chemical structure of pyrimethamine changes the pharmacological action of the drug. It is envisaged that this would lead to novel pharmacological models for antibacterial agents.




Figure 2: Infrared spectrum of pyrimethamine




Figure 3: Infrared spectrum of pyrimethamine-Ni complex




Figure 4: Infrared spectrum of pyrimethamine-Fe complex




Figure 5: Infrared spectrum of pyrimethamine-Co complex




Figure 6: Electronic spectrum of pyrimethamine




Figure 7: Electronic spectrum of pyrimethamine-Ni complex




Figure 8: Electronic spectrum of pyrimethamine-Fe complex




Figure 9: Electronic spectrum of pyrimethamine-Co complex

Table 1: Some physical properties of the pyrimethamine and its complexes

Complexes	Melting point (°C)	Yield (%)	Colour
$C_{12}H_{15}ClN_4$	207-212°C	-	White
$[NiC_{12}H_{15}ClN_4]$	223°C-230°C	36%	Pale green
$[FeC_{12}H_{15}ClN_4]$	218°C-223°C	73%	Pale green
$[CoC_{12}H_{15}ClN_4]$	220°C-229°C	97%	Pale yellow

Table 2: Zone of inhibition of pyrimethamine and its complexes at 250.00 mg/l concentration

Bacterials	[FeL]	[NiL]	[CoL]	L
<i>Nesseria gonorrhoea</i>	35.6±0.6 _a	22.5± 0.5 ^b	15.1±0.96 ^c	9.3±0.6 _d
<i>Proteus mirabilis</i>	27.5±0.9 _a	18.7±1.3 ^b	16.5± 1.4 ^c	8.3±0.3 _d

L = $C_{12}H_{15}ClN_4$, Values are means ± standard deviation of four determination. Means with different superscript in the same shows that are significantly different ($P < 0.05$) while means with the same superscript within the row do not differs significantly ($P > 0.05$).

Table 3: Zone of inhibition of pyrimethamine and its complexes at 125.00 mg/l concentration

Bacterials	[FeL]	[NiL]	[CoL]	L
<i>Nesseria gonorrhoea</i>	17.3±0.6 ^a	10.7±0.4 ^b	7.0±0.9 ^c	5.0±0.2 ^d
<i>Proteus mirabilis</i>	13.0±0.9 ^a	9.3±0.5 ^b	7.6±0.5 ^c	3.8 ±0.3 ^d

L = $C_{12}H_{15}ClN_4$, Values are means ± standard deviation of four determinations. Means with different superscript in the same shows that are significantly different ($P < 0.05$) while means with the same superscript within the row do not differs significantly ($P > 0.05$).

Table 4: Zone of inhibition of pyrimethamine and its complexes at 65.25 mg/l concentration

Bacterials	[FeL]	[NiL]	[CoL]	L
<i>Nesseria gonorrhoea</i>	8.7±0.4 ^a	4.7±0.5 ^b	1.9±0.3 ^c	1.6±0.3 ^d
<i>Proteus mirabilis</i>	6.9±0.9 ^a	4.0 ±0.2 ^b	3.0±0.2 ^c	0.5±0.6 ^d

L = $C_{12}H_{15}ClN_4$, Values are means ± standard deviation of four determinations. Means with different superscript in the same shows that are significantly different ($P < 0.05$) while means with the same superscript within the row do not differs significantly ($P > 0.05$).




Figure 10: Proposed structures of pyrimethamine metal complexes

MATERIALS AND METHODS

All chemicals used in this study were of analytical grade and were used without further purification. 5-(4-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine, $\text{NiSO}_4 \cdot 6\text{H}_2\text{O}$, $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, $\text{Co}(\text{NO}_3)_2$, methanol, chloroform, ethanol and distilled water were obtained from Sigma-Aldrich Chemical Company. The electronic spectra of the complexes in solution were scanned in the range 190-900nm on a Perkin Elmer 20 λ Uv-visible spectrophotometer. The samples were dissolved in 5ml of chloroform then 1ml of each of the solution was re-dissolved in another 5ml chloroform. The solutions were placed in Quartz cuvette of 1cm path length. The infrared spectra were collected on a 1000 FTIR Perkin Elmer spectrum Bx spectrophotometer equipped with caesium iodide window (4000-400 cm^{-1}) in KBr pellets. The melting point of both the ligand and complexes were determined using capillary tube method.

Synthesis of pyrimethamine metal complexes

The solution of pyrimethamine was prepared by dissolving 10 mmol (2.487g) of pyrimethamine in 15ml of methanol. Solution of respective metal salt obtained by dissolving 5mmol of the metal salt, $\text{NiSO}_4 \cdot 6\text{H}_2\text{O}$ (1.314 g); $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ (0.759 g); $\text{Co}(\text{NO}_3)_2$ (0.915 g) in 15ml of methanol. Pyrimethamine solution and the respective metal were stirred at 40°C for 1 hour. After 1 hour the solutions were allowed to cool for 24 hours for the reaction to go to completion. The product formed were filtered off and washed with distilled water and finally dried at room temperature.

Antibacterial Susceptibility Testing

Antibacteria, activity of the extract was evaluated using the following organisms; *Nesseria gonorrhea* and *P.mirabilis*. The ability of the ligand and

complexes to inhibit the growth of the bacteria was determined using agar-diffusion technique. Sterile glass pipettes of 8 mm diameter were used to make holes on prepared agar medium. Aliquots of 0.2 ml of the metal complex was introduced in the holes made on pre-seeded appropriate gelled media containing each isolate of organism, at different concentrations. Three plates were prepared, each containing four holes of 8 mm diameter for the different concentrations of the metal complex, for a specific isolate. In total, 14 petri-dishes were used and plates were incubated at 37°C for 24 hours in the incubator.

RESULTS AND DISCUSSION

The melting point of pyrimethamine and its complexes are shown in Table 1. The infrared spectra of pyrimethamine and the complexes are shown in Figures 2-5. The electronic spectra of pyrimethamine and its complexes are presented in Figures 6-9. The antibacterial zone of inhibition of pyrimethamine and its complexes are shown in Tables 2-4.

The increase in the melting point of the complexes suggests complexation. The changes in the colour of the complexes further support that coordination occurred since transition metal are coloured.

In the infrared spectrum of pyrimethamine, the N-H vibrational stretching frequency appeared at 3320.26 cm^{-1} but in the spectra of the metal complexes $[\text{NiC}_{12}\text{H}_{15}\text{ClN}_4]$, $[\text{FeC}_{12}\text{H}_{15}\text{ClN}_4]$ and $[\text{CoC}_{12}\text{H}_{15}\text{ClN}_4]$ it appeared at 3366.00, 3377.66 and 3340.00 cm^{-1} respectively. This suggests that N-H functional group was involved in coordination to the metal ions. C=N vibration stretching frequency appeared at 1636.27 cm^{-1} in pyrimethamine but in the $[\text{NiC}_{12}\text{H}_{15}\text{ClN}_4]$ and $[\text{FeC}_{12}\text{H}_{15}\text{ClN}_4]$ complexes, it

appeared at 1656.52 and 1647.26 cm^{-1} respectively. These shift suggest the involvement of C=N in complexation to Ni and Fe respectively. The vibration stretching frequency of C=N in $[\text{CoC}_{12}\text{H}_{15}\text{ClN}_4]$ appeared at 1637.66 cm^{-1} . This indicate the non-involvement of C=N in coordination to cobalt.

In the electronic spectrum of pyrimethamine, the absorption maxima were observed at 198.41, 248.08, 278.65 and 295.47 nm. These absorption bands were assigned $n-\pi^*$ and $\pi-\pi^*$ respectively. These transitions are due to intraligand charge transfer (ILCT). The absorption maxima in the electronic spectrum of $[\text{NiC}_{12}\text{H}_{15}\text{ClN}_4]$ were observed at 191.53, 255.94 and 263.28 nm were assigned $n-\pi^*$ and $\pi-\pi^*$ (ILCT) and the band at 295.43 nm were due to ligand to metal charge transfer (LMCT). The electronic absorption bands of $[\text{FeC}_{12}\text{H}_{15}\text{ClN}_4]$ complex were observed at 193.06, 208.34, 240.44, 255.73, 272.54 and 294.70 nm. These bands were assigned $n-\pi^*$, $\pi-\pi^*$ (ILCT) and ligand to metal charge transfer (LMCT). The absorption maxima of $[\text{CoC}_{12}\text{H}_{15}\text{ClN}_4]$ observed at 194.59 and 240.44 nm suggested $n-\pi^*$, $\pi-\pi^*$ (ILCT). The bands 254.96, 271.78 and 287.06 nm in the electronic spectrum of $[\text{CoC}_{12}\text{H}_{15}\text{ClN}_4]$ suggested ligand to metal charge transfer (LMCT).

The zone of inhibition of pyrimethamine against *Nesseria gonorrhea* and *Proteus mirabilis* at 250.00, 125.00 and 65.25 mg/l showed that it was significantly lower ($P < 0.05$) than the complexes. The zone of inhibition of $[\text{FeC}_{12}\text{H}_{15}\text{ClN}_4]$ against *Nesseria gonorrhea* and *Proteus mirabilis* at 250.00, 125.00 and 65.25 mg/l showed that it was significantly higher ($P < 0.05$) than $[\text{NiC}_{12}\text{H}_{15}\text{ClN}_4]$ and $[\text{CoC}_{12}\text{H}_{15}\text{ClN}_4]$. This suggests that the complexes were more potent than the parent ligand against the bacteria strains used.

Based on the electronic and infrared spectrum analysis, the following structures (Figure 10) were proposed for the complexes.

CONCLUSION

Pyrimethamine complexes of Ni(II), Fe(II) and Co(II) have been synthesized. The chelating agent behaved as a tetradentate ligand towards nickel and iron and behaved as bidentate ligand towards cobalt ion. The complexes were more potent than the parent ligand against *Nesseria gonorrhea* and *Proteus mirabilis*.

ACKNOWLEDGMENTS

We wish to thank Mr Ogunsanya Kayode of University of Ibadan for supporting us with Infrared and electronic spectra analysis.

REFERENCES

- [1] Common side effect of Darapim(pyrimethamine), Drug center-RxList, *RxList* Retrieved 2016-11-07.
- [2] Daraprim-FDA prescribing information, side effects and uses, www.drugs.com. Retrieved 2016-11-07
- [3] Gatton ML., (2004) Evolution of resistance to sulfadoxine-pyrimethamine in *Plasmodium falciparum*, *Antimicrob Agents Chemother.* 48(6): 2116 –2123.
- [4] "WHO Model List of Essential Medicines". World Health Organization. October 2013. Retrieved 22 April 2014.
- [5] Mishra N., Poonia K., Kumar D., (2013). "An overview of biological aspects of Schiff base metal complexes," *International Journal of Advancements in Research &Technology*, 2(8): 52–66,
- [6] Shelke VA., Jadhav SM., Patharkar VR., Shankarwar SG., Munde AS., Chondhekar TK., (2012). "Synthesis, spectroscopic characterization and thermal studies of some rare earth metal complexes of unsymmetrical tetradentate Schiff base ligand," *Arabian Journal of Chemistry*,5(4): 501–507.
- [7] Osowole AA., Kolawole GA., Fagade OE., (2005) "Synthesis, physicochemical, and biological properties of nickel(II), copper(II), and zinc(II) complexes of an unsymmetrical tetradentate Schiff base and their adducts," *Synthesis and Reactivity in Inorganic, Metal-Organic and Nano-Metal Chemistry*, 35(10):829–836.
- [8] T'umer M., K'oksal H., Serin S., Digrak M., (1999) "Antimicrobial activity studies of mononuclear and binuclear mixed-ligand copper(II) complexes derived from Schiff base ligands and 1,10-phenanthroline," *Transition Metal Chemistry*, 24(1): 13–17.
- [9] Zishen W., Zhiping L., Zhenhuan Y., (1993). "Synthesis, characterization and antifungal activity of glycylglycine Schiff base complexes of 3d transition metal ions," *Transition Metal Chemistry*, 18(3): 291–294
- [10] Gaballa AS., Asker MS., Barakat AS., Teleb SM., (2007). "Synthesis, characterization and biological activity of some platinum(II) complexes with Schiff bases derived from Salicylaldehyde, 2-furaldehyde and phenylene diamine," *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, 67(1):114–121.